Campylobacter spp. are major causes of gastrointestinal infections worldwide, and are commonly identified using modified-charcoal-cefoperazone-deoxycholate agar (mCCDA). However, the efficacy of this screening technique is often hindered by overgrowth of competing flora, such as extended-spectrum β-lactamase (ESBL)-producing Escherichia coli. Thus, in the present study we supplemented mCCDA with a recently developed ESBL inhibitor, avibactam (A-mCCDA). We inoculated mCCDA and A-mCCDA plates with 25 strains each of Campylobacter spp. and ESBL-producing E. coli, and thereby determined that the optimum avibactam concentration required to inhibit ESBL-producing E. coli was 0.0625 mg/L. At this concentration, a significantly higher proportion of Campylobacter spp. was isolated using A-mCCDA compared to that using mCCDA (P < 0.05). Thus, the results of the present study support the use of A-mCCDA to improve current Campylobacter screening methods.

弯曲杆菌属。是全球胃肠道感染的主要原因，通常使用修饰的木炭-头孢哌酮-脱氧胆酸盐琼脂（mCCDA）进行鉴定。然而，这种筛选技术的功效通常由于竞争性菌群的过度生长而受到阻碍，这些菌群例如产生广谱β-内酰胺酶（ESBL）的大肠杆菌。因此，在本研究中，我们用最近开发的ESBL抑制剂阿维巴坦（A-mCCDA）补充了mCCDA。我们用弯曲杆菌属菌种分别接种25株mCCDA和A-mCCDA板。和产生ESBL的大肠杆菌，从而确定抑制产生ESBL的大肠杆菌所需的最佳avibactam浓度为0.0625 mg / L。在该浓度下，弯曲杆菌属物种的比例明显更高。与使用mCCDA进行分离相比，使用A-mCCDA进行了分离（P  <0.05）。因此，本研究的结果支持使用A-mCCDA来改善当前的弯曲杆菌筛选方法。